Key Points Palisade Bio has dosed the first patient in ASCENTRA-UC, a Phase 2b study of once-daily oral PALI-2108. The randomized, placebo-controlled trial plans to…
Key Points Humacyte received U.S. Patent No. 12,742,144, covering aspects of manufacturing, sterilization, storage and shipping for Symvess and other bioengineered human tissues. The patent…
October 27, 2026
Firefly Highlights Versus Platform in Non-Invasive Brain-Computer Interface Strategy
Key Points Firefly’s commercially available Versus platform combines a wireless EEG headset with interactive training software. The company reports more than 3,000 headsets shipped and…
October 27, 2026
Vanda Reports Positive Phase 3 Results for NEREUS in Preventing GLP-1-Related Vomiting
Key Points Vanda’s NEREUS reduced the proportion of participants who vomited after semaglutide from 58.5% with placebo to 43.0%. The trial met its primary endpoint,…
Key Points Cumberland Pharmaceuticals plans to seek FDA approval for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy, or DMD. The FDA granted rolling…
October 26, 2026
ArriVent Reports Initial Phase 1 Data for ARR-217, Including a 44.8% Response Rate in Colorectal Cancer at One Dose
ArriVent BioPharma, Inc. (NASDAQ: AVBP), a clinical-stage company developing cancer therapies, announced on October 25, 2026 initial Phase 1 results for ARR-217, an antibody-drug conjugate…
October 26, 2026
Immatics Reports ESMO Data for Two PRAME Programs, Including a 32% Response Rate for IMA402 in Melanoma
Immatics N.V. (NASDAQ: IMTX), a clinical-stage company developing cancer therapies that target the PRAME protein, announced on October 24, 2026 updated clinical data from two…
October 23, 2026
BioLineRx and Hemispherian Report Encouraging GLIX1 Combination Results in Ovarian Cancer Models
Key Points GLIX1 enhanced the activity of three PARP inhibitors in laboratory studies of HR-proficient ovarian cancer cells. In a mouse model using patient-derived ovarian…
October 23, 2026
Evaxion Reports 89% Vaccine Target Precision and Three-Year Durability for EVX-01 in Advanced Melanoma
Evaxion A/S (NASDAQ: EVAX), a clinical-stage company that designs immunotherapies with its AI-Immunology platform, announced on October 23, 2026 new three-year immune and clinical data…
October 22, 2026
Verrica Unlocks Full $27.5 Million Credit Facility to Support YCANTH Growth and Warts Trials
Key Points Verrica met revenue, growth and operational milestones that unlocked an additional $15 million in borrowing capacity. The full $27.5 million facility is now…
October 22, 2026
Korro Reports Encouraging RNA-Editing Results for KRRO-111, Targets Regulatory Submission in 2027
Key Points Korro Bio’s experimental KRRO-111 showed strong RNA-editing activity in laboratory and mouse studies for alpha-1 antitrypsin deficiency, or AATD. Repeat-dose mouse studies achieved…
October 22, 2026
Sagimet Doses First Patient in Phase 3 U.S. Acne Trial, Targets Results in Late 2027
Key Points Sagimet Biosciences has dosed the first patient in AURORA, its pivotal U.S. Phase 3 trial of denifanstat for moderate to severe acne. The…